Bayer AG news
The European Patent Office has reversed a first instance decision and maintained a Bayer patent (EP 1 845 961) on the once-daily administration of rivaroxaban (Xarelto™; 10, 15 and 20 mg). The 2.5 mg dose is not affected.
Several generic drug manufacturers had initially successfully opposed the patent. With this decision of the European Patent Office, this patent is still valid until mid-January 2026, therefore almost two years longer than t
- Darolutamide now has indications in both non-metastatic castration-resistant prostate cancer (nmCRPC) for men at high risk of developing metastatic disease and metastatic hormone-sensitive prostate cancer (mHSPC)
- Today’s approval under the FDA’s Real-Time Oncology Review (RTOR) pilot program was based on the pivotal Phase III ARASENS trial, which showed a significant overall survival (OS) benefit with darolutamide plus androgen deprivation therapy (ADT) and doceta
Tavros to receive $17.5M upfront, up to $430.5M in milestone payments for initial four programs, and certain royalties over agreement term / Vividion will have rights to opt-in to up to five more targets for up to $482M in additional payments /Partnership to define novel drug targets and biomarkers, in addition to positioning existing compounds
Tavros Therapeutics, Inc., a precision oncology platform company leading the new frontier of targeted therapies exploiting
Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced that Jenna Goldberg, M.D., has joined the company as Chief Medical Officer. Dr. Goldberg brings industry leadership experience to Vividion, having held multiple senior medical rol
- Acquisition is part of Bayer’s innovation strategy in radiology
- Blackford Analysis provides cutting-edge radiology AI (artificial intelligence) platform technology
- Following closing of the acquisition, Blackford Analysis to become part of Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneurial culture
Bayer today announced the acquisition of